ASP1570

DRUG2 trials

Sponsors

Astellas Pharma Global Development Inc., Astellas Pharma Global Development, Inc.

Conditions

Advanced Solid Tumors

Phase 1

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

TerminatedNCT05083481

Astellas Pharma Global Development, Inc.Advanced Solid Tumors

Start: 2021-10-19End: 2026-05-11Updated: 2026-08-14

A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination with Pembrolizumab and/or Standard Therapies Including Chemotherapy and/or Immunotherapy in Participants with Locally Advanced or Metastatic Solid Tumors

RecruitingCTIS2023-505084-37-00

Astellas Pharma Global Development Inc.Advanced Solid Tumors

Start: 2025-03-17Target: 98Updated: 2025-12-19

Related Papers

Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer

Molecular Cancer Therapeutics2025-03-266 citations

Abstract A004: Enhanced antitumor immunity by ASP1570 in mouse models: A novel DGKζ inhibitor offers a potential immunotherapy for treating cancer

Molecular Cancer Therapeutics2023-12-01

754 A phase 1/2 study of ASP1570 in participants with locally advanced or metastatic solid tumors who have progressed on, or are ineligible for, all available standard therapies

Regular and Young Investigator Award Abstracts2022-11-011 citations